sk&f 83959 has been researched along with oxidopamine in 3 studies
| Studies (sk&f 83959) | Trials (sk&f 83959) | Recent Studies (post-2010) (sk&f 83959) | Studies (oxidopamine) | Trials (oxidopamine) | Recent Studies (post-2010) (oxidopamine) |
|---|---|---|---|---|---|
| 94 | 0 | 46 | 8,630 | 6 | 2,407 |
| Protein | Taxonomy | sk&f 83959 (IC50) | oxidopamine (IC50) |
|---|---|---|---|
| Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) | 8 | |
| DNA repair protein RAD52 homolog | Homo sapiens (human) | 0.779 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Friedman, E; Goswami, S; Zhen, X | 1 |
| Osborn, CV; Wirtshafter, D | 1 |
| Chen, J; Ma, L; Wang, F; Zhang, H; Zhen, X | 1 |
3 other study(ies) available for sk&f 83959 and oxidopamine
| Article | Year |
|---|---|
The role of the phosphatidyinositol-linked D1 dopamine receptor in the pharmacology of SKF83959.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Brain Chemistry; Dopamine Agonists; Dopamine Antagonists; Hippocampus; Inositol 1,4,5-Trisphosphate; Male; Neostriatum; Oxidopamine; Phosphatidylinositols; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Stereotyped Behavior; Sympathectomy, Chemical; Sympatholytics; Type C Phospholipases | 2005 |
The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Benzazepines; Brain; Corpus Striatum; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Male; Models, Animal; Motor Activity; Oxidopamine; Proto-Oncogene Proteins c-fos; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Signal Transduction; Sympathectomy, Chemical | 2005 |
Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Movement; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Serotonin Antagonists; Spiperone; Sympatholytics; Time Factors | 2007 |